玻璃体手术联合眼内激光治疗出血性玻璃体视网膜疾病  

Vitrectomy and endolaser for hemorrhagic vitreoretinal diseases

作　　者：谢怀林[1] 王善洁[1] 蒋艳华[1] 杨帆[1] 

机构地区：[1]广西壮族自治区南溪山医院眼科,广西桂林541002

出　　处：《临床眼科杂志》2008年第5期420-421,共2页Journal of Clinical Ophthalmology

摘　　要：目的探讨玻璃体切除术联合眼内光凝治疗出血性璃体视网膜疾病的临床效果。方法对37例(37只眼)玻璃体积血行玻璃体切除术联合眼内光凝、膜剥离、部分行眼内惰性气体或硅油填充。结果增生性糖尿病视网膜病变13只眼,视网膜静脉阻塞11只眼,视网膜静脉周围炎8只眼,孔源性视网膜脱离玻璃体积血5只眼。术后随访3～36个月,平均(11±2.4)个月,37只眼视力均有不同程度的提高,0.05以上者31只眼(83.78%),与术前相比差异有统计学意义(P<0.05)。结论玻璃体手术联合眼内激光是治疗出血性玻璃体视网膜疾病的有效方法。Objective To study the chnical curatived effects of vitrectomy for vitreoretinal bleeding disease. Methods A totals of 37cases （37eyes） of vitreous hemorrhage underwent vitrectomy Combined with retinal photocoagulation, membrane peelingand and the application of long effective materials according to particular situation respectively. Results Conditions of the eyes included diabetic retinopathy in 13 eyes, retinal vein occlusion in 11 eyes ,Ealea＇ disease in 8 eyes, rhegmatogenous vitreous hemorrhage in 5 eyes . Postoperative follow-up was 3 - 36 months with medioan （ 11 ± 2.4 ） months. All of the visual acuity was improved to a certain extent 31 eyes above 0.05 （ 83.78% ）, there was significant difference between preoperative and postoperative vision （ P 〈 0.05 ）. Conclusion Vitrectomy is an effective method to hemorrhagic vitreoretinal diseases.

关 键 词：玻璃体积血 玻璃体切除术 激光光凝术 

分 类 号：R779.6[医药卫生—眼科]